vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and MAXLINEAR, INC (MXL). Click either name above to swap in a different company.
MAXLINEAR, INC is the larger business by last-quarter revenue ($137.2M vs $86.8M, roughly 1.6× IOVANCE BIOTHERAPEUTICS, INC.). On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 22.1%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.
IOVA vs MXL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $137.2M |
| Net Profit | — | $-45.1M |
| Gross Margin | 67.4% | 57.5% |
| Operating Margin | -84.7% | 30.0% |
| Net Margin | — | -32.9% |
| Revenue YoY | 17.7% | 43.0% |
| Net Profit YoY | — | -203.0% |
| EPS (diluted) | — | $-0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $137.2M | ||
| Q4 25 | $86.8M | $136.4M | ||
| Q3 25 | $67.5M | $126.5M | ||
| Q2 25 | $60.0M | $108.8M | ||
| Q1 25 | $49.3M | $95.9M | ||
| Q4 24 | $73.7M | $92.2M | ||
| Q3 24 | $58.6M | $81.1M | ||
| Q2 24 | $31.1M | $92.0M |
| Q1 26 | — | $-45.1M | ||
| Q4 25 | — | $-14.9M | ||
| Q3 25 | $-91.3M | $-45.5M | ||
| Q2 25 | $-111.7M | $-26.6M | ||
| Q1 25 | $-116.2M | $-49.7M | ||
| Q4 24 | — | $-57.8M | ||
| Q3 24 | $-83.5M | $-75.8M | ||
| Q2 24 | $-97.1M | $-39.3M |
| Q1 26 | — | 57.5% | ||
| Q4 25 | 67.4% | 57.6% | ||
| Q3 25 | 43.0% | 56.9% | ||
| Q2 25 | 5.5% | 56.5% | ||
| Q1 25 | -0.8% | 56.1% | ||
| Q4 24 | 68.7% | 55.6% | ||
| Q3 24 | 46.2% | 54.4% | ||
| Q2 24 | -0.8% | 54.6% |
| Q1 26 | — | 30.0% | ||
| Q4 25 | -84.7% | -10.9% | ||
| Q3 25 | -140.7% | -32.7% | ||
| Q2 25 | -189.8% | -22.6% | ||
| Q1 25 | -245.8% | -48.0% | ||
| Q4 24 | -117.5% | -44.7% | ||
| Q3 24 | -152.1% | -82.3% | ||
| Q2 24 | -327.6% | -44.4% |
| Q1 26 | — | -32.9% | ||
| Q4 25 | — | -10.9% | ||
| Q3 25 | -135.3% | -36.0% | ||
| Q2 25 | -186.2% | -24.4% | ||
| Q1 25 | -235.5% | -51.8% | ||
| Q4 24 | — | -62.8% | ||
| Q3 24 | -142.7% | -93.4% | ||
| Q2 24 | -312.2% | -42.7% |
| Q1 26 | — | $-0.52 | ||
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.52 | ||
| Q2 25 | $-0.33 | $-0.31 | ||
| Q1 25 | $-0.36 | $-0.58 | ||
| Q4 24 | $-0.24 | $-0.68 | ||
| Q3 24 | $-0.28 | $-0.90 | ||
| Q2 24 | $-0.34 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $61.1M |
| Total DebtLower is stronger | — | $123.8M |
| Stockholders' EquityBook value | $698.6M | $454.2M |
| Total Assets | $913.2M | $771.3M |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.1M | ||
| Q4 25 | $297.0M | $72.8M | ||
| Q3 25 | $300.8M | $111.9M | ||
| Q2 25 | $301.2M | $108.6M | ||
| Q1 25 | $359.7M | $102.8M | ||
| Q4 24 | $323.8M | $118.6M | ||
| Q3 24 | $397.5M | $148.5M | ||
| Q2 24 | $412.5M | $185.1M |
| Q1 26 | — | $123.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $454.2M | ||
| Q4 25 | $698.6M | $451.9M | ||
| Q3 25 | $702.3M | $464.7M | ||
| Q2 25 | $698.5M | $488.3M | ||
| Q1 25 | $767.9M | $493.2M | ||
| Q4 24 | $710.4M | $516.3M | ||
| Q3 24 | $773.5M | $556.9M | ||
| Q2 24 | $768.5M | $617.3M |
| Q1 26 | — | $771.3M | ||
| Q4 25 | $913.2M | $796.4M | ||
| Q3 25 | $904.9M | $808.1M | ||
| Q2 25 | $907.4M | $863.7M | ||
| Q1 25 | $966.7M | $855.3M | ||
| Q4 24 | $910.4M | $864.6M | ||
| Q3 24 | $991.1M | $895.3M | ||
| Q2 24 | $964.3M | $973.2M |
| Q1 26 | — | 0.27× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | — |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-52.6M | $10.4M | ||
| Q3 25 | $-78.7M | $10.1M | ||
| Q2 25 | $-67.4M | $10.5M | ||
| Q1 25 | $-103.7M | $-11.4M | ||
| Q4 24 | $-73.3M | $-27.8M | ||
| Q3 24 | $-59.0M | $-30.7M | ||
| Q2 24 | $-98.4M | $-2.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $6.7M | ||
| Q3 25 | $-89.5M | $4.4M | ||
| Q2 25 | $-74.9M | $9.3M | ||
| Q1 25 | $-109.9M | $-13.4M | ||
| Q4 24 | $-77.5M | $-30.0M | ||
| Q3 24 | $-61.3M | $-34.9M | ||
| Q2 24 | $-98.9M | $-5.7M |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | 4.9% | ||
| Q3 25 | -132.7% | 3.5% | ||
| Q2 25 | -124.9% | 8.6% | ||
| Q1 25 | -222.8% | -14.0% | ||
| Q4 24 | -105.1% | -32.6% | ||
| Q3 24 | -104.6% | -43.0% | ||
| Q2 24 | -317.9% | -6.2% |
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 2.7% | ||
| Q3 25 | 16.1% | 4.5% | ||
| Q2 25 | 12.4% | 1.1% | ||
| Q1 25 | 12.6% | 2.1% | ||
| Q4 24 | 5.7% | 2.4% | ||
| Q3 24 | 3.9% | 5.1% | ||
| Q2 24 | 1.4% | 3.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
MXL
Segment breakdown not available.
